Magma Corporate Finance has advised Copley Scientific, the world leader in inhaler testing equipment, on its acquisition of Novi Systems a company with market-leading expertise in the automation of inhaler testing.

The acquisition means the Copley product range is extended and a broader platform for the development of new inhaler testing solutions is secured.

Mark Copley, CEO Copley Scientific said “We’ve known and respected Novi for many years, and the two companies are highly complementary with a strong set of shared values.  Like Copley, Novi is a UK-based family business, with a ‘can do’ problem solving approach and a reputation for engineering excellence.  Our combined strengths will undoubtedly provide customers of both companies with new opportunities to streamline and enhance their inhaler testing capabilities.”

Will Lodder (Partner) and Shaf Bheda (Senior Manager) acted as financial advisors to Copley, with Shaf commenting “This deal means the coming together of two leaders in the inhaler testing space and provides clear strategic benefits for the combined business and their respective customers.  It has been a pleasure to have worked with Copley and Knights on the transaction.”

Richard Postlethwaite, COO said “Magma’s input and advice during the transaction was invaluable and we would like to thank Shaf and Will for their significant help throughout.”